Form 4 for MNKD MANNKIND CORP
Accepted 2026-07-17 21:44:59 ET · period of report 2026-07-15 · accession 0001193125-26-308133 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-07-17 21:44 | 2026-07-15 | MNKD | Castagna Michael | CEO, Dir | M - OptEx | $0.00 | +350.3K | 2.80M | +14% | $0 |
| DM | 2026-07-17 21:44 | 2026-07-15 | MNKD | Castagna Michael | CEO, Dir | F - Tax | $4.09 | -363.2K | 2.43M | -13% | -$1.49M |
| D | 2026-07-17 21:44 | 2026-07-15 | MNKD | Castagna Michael | CEO, Dir | M - OptEx | $0.00 | -350.3K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.01 Par Value | 2026-07-15 | M | A | 350,260 | $0.00 | 2,796,979 | D | — | — | (F1) A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 350,260 shares. The acquisition of 422,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 71,740 shares were forfeited in accordance with the performance vesting criteria. (F2) Includes 4,409 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026. |
| 2 | Common | Common Stock, $0.01 Par Value | 2026-07-15 | F | D | 192,819 | $4.09 | 2,604,160 | D | — | — | (F3) Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| 3 | Common | Common Stock, $0.01 Par Value | 2026-07-15 | F | D | 47,481 | $4.09 | 2,556,679 | D | — | — | (F3) Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| 4 | Common | Common Stock, $0.01 Par Value | 2026-07-15 | F | D | 63,996 | $4.09 | 2,492,683 | D | — | — | (F3) Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| 5 | Common | Common Stock, $0.01 Par Value | 2026-07-15 | F | D | 58,904 | $4.09 | 2,433,779 | D | — | — | (F3) Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| 6 | Derivative | Performance Restricted Stock Unit | 2026-07-15 | M | D | 350,260 | $0.00 | 0 | D | — · — to — | 350,260 Common Stock, $0.01 Par Value | (F4) Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. (F1) A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 350,260 shares. The acquisition of 422,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 71,740 shares were forfeited in accordance with the performance vesting criteria. (F1) A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 350,260 shares. The acquisition of 422,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 71,740 shares were forfeited in accordance with the performance vesting criteria. (F1) A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 350,260 shares. The acquisition of 422,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 71,740 shares were forfeited in accordance with the performance vesting criteria. (F1) A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 350,260 shares. The acquisition of 422,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 71,740 shares were forfeited in accordance with the performance vesting criteria. |